Low molecular weight heparins: Differences and similarities in approved preparations in the United States

Clinical and Applied Thrombosis/Hemostasis

Volumn 5, Issue SUPPL. 1, 1999, Pages

  Bick, Rodger L ^a,c   Fareed, Jawed ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Clinical trials; Differentiation; Low molecular weight heparin; Pharmacodynamics

Indexed keywords

ARDEPARIN; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN;

ANIMAL EXPERIMENT; BLEEDING; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG FORMULATION; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT INDICATION; UNITED STATES;

EID: 0032732653     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/10760296990050s111     Document Type: Conference Paper

References (13)

1. Fareed J, Jeske W, Hoppensteadt D, et al. Are the available low molecular weight heparins the same? Semin Thromb Hemost 1996; 22:77.
2. Fareed J, Hoppensteadt D, Jeske W, et al. The available low molecular weight heparin preparations are not the same. Clin Appl Thromb Hemost 1997;3(Suppl 1):38.
3. Fareed J, Walenga JM, Hoppensteadt D, et al. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann N Y Acad Sci 1989;556:333.
4. Fareed J, Walenga JM, Racanelli A, et al. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Haemostasis 1988; 18(Suppl 3):33.
5. Bick RL, Fareed J, Walenga JM, et al. Heparin releasable tissue factor pathway inhibitor during interventional cardiovascular procedures. Blood 1994;84(Suppl 1):81A.
6. Farag SS, Savoia H, O'Malley CJ, et al. Lack of in vitro cross-reactivity predicts safety of low-molecular-weight heparins in heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 1997; 3:58.
7. Walenga JM, Koza MJ, Lewis BE, et al. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost 1996; 2(Suppl 1):21.
8. Slocum MM, Adams JG, Teel R, et al. Use of enoxaparine in patients with heparin-induced thrombocytopenia syndrome. J Vasc Surg 1996;23:839.
9. Bick RL. Hep̄arin therapy and monitoring: guidelines and practice parameters for clinical and laboratory approaches. Clin Appl Thromb Hemost 1996;2(Suppl 1):12.
10. Bick RL. Current concepts of heparin therapy. Laboratory Medicine 1995;26:261.
11. Barrowcliffe TW. Low molecular weight heparins. Br J Haematol 1995;90:1.
12. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998;114(Suppl):489.
13. Laposata M, Green D, Van Cott EM, et al. CAP Conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998;122:799.